Not a lot new during this presentation but just one note:
1. RIGL is waiting to see exactly what PFE's statement on what it's doing in various strategic areas (#msg-59431699) means for its partnership with PFE on R343, the inhaled Syk inhibitor targeting asthma. The CEO said that either PFE or RIGL would test the drug further in Phase 2 (depending on PFE's decision on the program), but RIGL believes that R343 is the first novel mechanism drug to work in blinded placebo and active-controlled challenge studies with steroids in asthma in 30 years. So far at least, the drug apparently works as well as steroids, but much quicker. The CEO cautioned that further studies in chronic asthma patients will be needed to determine how useful the drug will be. [Based on the tone in the CC and PFE's prior statement which seemed to be pretty clear that it will be ending development in asthma, among other areas, I expect PFE will terminate the partnership at some point which I think might create a nice entry point for RIGL.]
Market Data 
Markets 
AI
